HighTower Advisors’s Axsome Therapeutics AXSM Stock Holding History

HighTower Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.57M	Buy	56,633 +661	+1%	+$114K	0.01%	901
2025 Q4	$10.2M	Sell	55,972 -1,143	-2%	-$160K	0.01%	856
2025 Q3	$6.94M	Buy	57,115 +46,153	+421%	+$5.2M	0.01%	1005
2025 Q2	$1.14M	Sell	10,962 -2,588	-19%	-$274K	﹤0.01%	1926
2025 Q1	$1.58M	Buy	13,550 +90	+0.7%	+$10.3K	﹤0.01%	1649
2024 Q4	$1.14M	Buy	+13,460	New	+$1.24M	﹤0.01%	1873
2023 Q3	–	Sell	-2,778	Closed	-$199K	–	3579
2023 Q2	$199K	Buy	+2,778	New	+$205K	﹤0.01%	2872
2023 Q1	–	Sell	-3,328	Closed	-$256K	–	3414
2022 Q4	$256K	Buy	+3,328	New	+$199K	﹤0.01%	2589

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's AXSM Position: Q1 2026 in Review

HighTower Advisors increased its Axsome Therapeutics (AXSM) stake by 1.2% in Q1 2026, buying an estimated $114K and bringing the position to 56,633 shares worth $9.57M. The position accounts for 0.01% of the portfolio, ranked #901.

HighTower Advisors first reported a position in AXSM in Q4 2022 and has held it in 8 quarters since. The position peaked at $10.2M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

HighTower Advisors held 56,633 shares of Axsome Therapeutics worth $9.57M as of Q1 2026.
HighTower Advisors bought 661 Axsome Therapeutics shares in Q1 2026, an estimated $114K.
Axsome Therapeutics made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #901 holding.
HighTower Advisors first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 8 quarters since.
HighTower Advisors's Axsome Therapeutics position peaked at $10.2M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.